All noncirrhotic prior null responders receiving @ weeks of SOF along with another direct-acting antiviral agent plus RBV achieved SVR@-@ of @ ( @ % ) of those receiving SOF , LDV , and RBV and @ of @ ( @ % ) of those receiving SOF , GS-@ , and RBV .